Document Detail

Activity of paclitaxel by three-hour infusion in Asian patients with metastatic undifferentiated nasopharyngeal cancer.
MedLine Citation:
PMID:  9602268     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Despite its moderate anti-tumour activity in head and neck cancers there have been no reports on the activity of paclitaxel in patients with nasopharyngeal cancer, a highly chemosensitive tumour. A phase II study was thus initiated to determine the objective response rate and toxicity of paclitaxel in patients with previously untreated metastatic nasopharyngeal cancer. PATIENTS AND METHODS: Twenty-four patients with previously untreated measurable metastatic nasopharyngeal carcinoma were accrued, one of them ineligible because of concomitant beta-blocker usage. Male:female ratio was 19:5, with a median age of 46 years. All had previously received radiotherapy but were chemotherapy-naïve. The great majority (20 of 24) had undifferentiated carcinoma. Paclitaxel (Anzatax, Faulding Pharmaceuticals) 175 mg/m2 was given intravenously over three hours every 21 days after premedication with oral dexamethasone and intravenous diphenhydramine and cimetidine. RESULTS: There were five (21.7%) partial responses while eight patients remained stable. Median response duration was 7.5 months and median survival was 12 months. The main toxicity was haematological, with grade 1-2 neutropenia in 19% and grade 3-4 neutropenia in 4.5% of cycles. Three cycles were complicated by grade 3-4 anaemia and one patient required a blood transfusion. No thrombocytopenia was seen. Peripheral neuropathy was frequent (20 of 23 patients) but mild. Alopecia was complete in 14 patients. There were no cardiac toxicity or hypersensitivity reactions. CONCLUSIONS: Paclitaxel is well tolerated even in previously irradiated patients with metastatic nasopharyngeal cancer. Single-agent activity was 22% and its inclusion into combination chemotherapy regimens should be studied.
E Au; E H Tan; P T Ang
Related Documents :
20523088 - Long-term efficiency and toxicity of adjuvant dose-dense sequential adriamycin-paclitax...
10190788 - Carboplatin and paclitaxel, alone and in combination: dose escalation, measurement of r...
11098078 - Successful treatment of two patients with recurrent endometrial cancer by weekly paclit...
7916038 - Phase ii trial of paclitaxel in patients with progressive ovarian carcinoma after plati...
21550558 - First- or second-line gefitinib therapy in unknown epidermal growth factor receptor mut...
23409768 - Percutaneous radiofrequency ablation (rfa) or robotic radiosurgery (rrs) for salvage tr...
Publication Detail:
Type:  Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Annals of oncology : official journal of the European Society for Medical Oncology / ESMO     Volume:  9     ISSN:  0923-7534     ISO Abbreviation:  Ann. Oncol.     Publication Date:  1998 Mar 
Date Detail:
Created Date:  1998-07-23     Completed Date:  1998-07-23     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  9007735     Medline TA:  Ann Oncol     Country:  NETHERLANDS    
Other Details:
Languages:  eng     Pagination:  327-9     Citation Subset:  IM    
Department of Medical Oncology, Singapore General Hospital, Singapore.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aged, 80 and over
Antineoplastic Agents, Phytogenic / administration & dosage*,  adverse effects
Carcinoma / diagnosis,  drug therapy*,  mortality,  secondary*
Disease-Free Survival
Drug Administration Schedule
Infusions, Intravenous
Middle Aged
Nasopharyngeal Neoplasms / diagnosis,  drug therapy*,  mortality
Paclitaxel / administration & dosage*,  adverse effects
Survival Rate
Treatment Outcome
Reg. No./Substance:
0/Antineoplastic Agents, Phytogenic; 33069-62-4/Paclitaxel

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Coincidence of seminoma and sarcoidosis: a myth or fact?
Next Document:  First-line treatment of advanced non-small-cell lung cancer with docetaxel and cisplatin: a multicen...